Indoximod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Indoximod Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Indoximod can convert its Small molecule drug profile and IDO1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Indoximod (query alias: Indoximod) |
|---|---|
| Modality / target | Small molecule drug; IDO1; IDO1 inhibitors |
| Highest global status | Phase 2 |
| Originator | NewLink Genetics Corp. |
| Active developers | Augusta University Research Institute |
The MCP disease footprint includes Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04049669 | Phase 2 | Active, not recruiting | 130 | 8-month iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria) |
| NCT03852446 | Early Phase 1 | Completed | 56 | Area Under the Plasma Concentration-Time Curve |
| NCT03372239 | Phase 1 | Completed | 48 | Area Under the Plasma Concentration-Time Curve |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Phase 1/2; n=131; evaluation: not stated. Reported fields: Phase 1 Regimen Limiting Toxicity of the Combination of Indoximod and Ipilimumab = 1 Participants ; -; Phase 1 Regimen Limiting Toxicity of the Combination of Indoximod and Ipilimumab = 0 Participants
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase 1/2; n=157; evaluation: not stated. Reported fields: -; Regimen Limiting Toxicity = 0 Participants ; Regimen Limiting Toxicity = 0 Participants
Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+ T cells whose on-treatment expansion is predictive of long-term outcome.
Not Applicable; n=30; evaluation: Positive. Reported fields: CEI = 8.6 % ; CEI = 8.6 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Indoximod addresses Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IDO1 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-23 | Hornet emerges from stealth with a strategic partnership with Kyowa Kirin | Phase 1 | Financial terms not disclosed |
| 2019-04-02 | BriaCell plans to assess the impact of combining Bria-IMT with Incyte's INCMGA-0012 and epacadostat in treating advanced breast cancer. | Not disclosed | Financial terms not disclosed |
| 2018-11-02 | Kyowa Hakko Kirin Announces a Phase 1 Clinical Study of its IDO inhibitor in solid tumor, under a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods and compositions utilizing IDO1-dependent vascularizing cells for the treatment of pathological conditions involving neovascularization”. The milestone feed surfaced a patent-application signal described as “A process for the preparation of indoximod”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
